Literature DB >> 1182692

Tissue-specific synthesis of methotrexate polyglutamates in the rat.

V M Whitehead, M M Perrault, S Stelcner.   

Abstract

Purified tritium-labeled methotrexate was administered to rats and Sephadex G-15 gel chromatography was used to study the formation of poly-gamma-glutamyl metabolites of methotrexate in different tissues. These metabolities were recognized as tritium-labeled antifolate fractions and were identified by their response to serum pterolypolyglutamate hydrolases and by cochromatography with authentic standards. After doses equivalent to 15 to 20 mg for man, rat liver and kidney were found to contain both 4-amino 10-methylpterolyglutamyl-gamma-glutamic acid and 4-amino-10-methylpterolyglutamyl-gamma-glutamyl-gamma-glutamic acid. With one-third of the dose, only 4-amino 10-methylpteroylglutamyl-gamma-glutamic acid was found. Synthesis of methotrexate polyglutamates in liver and kidney was limited to the interval immediately following methotrexate administration and appeared to occur by sequential addition of single glutamyl residues to so-called "free" intracellular methotrexate. No synthesis of methotrexate polyglutamates was demonstrated in small intestine or thymus. After formation, 4-amino-10-methylpteroyglutamyl-gamma-glutamic acid disappeared from liver and kidney with a half-time of 6.5 days. The effect of these metabolites of methotrexate of cell metabolism is unknown.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1182692

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

2.  Methotrexate (MTX) concentration in tumors following low-dose MTX.

Authors:  N J Winick; B A Kamen; A Streckfuss; J Craig; F McGuirt; R L Capizzi; F Sklar; D Coln
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.

Authors:  S Koizumi; G A Curt; R L Fine; J D Griffin; B A Chabner
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

Review 4.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

5.  Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker.

Authors:  J Hendel; H Brodthagen
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Pharmacokinetics of methotrexate in erythrocytes in psoriasis.

Authors:  J Hendel; A Nyfors
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate.

Authors:  G P Browman; L Booker; P Spiegl
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.

Authors:  J Jolivet; R L Schilsky; B D Bailey; J C Drake; B A Chabner
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

9.  Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy.

Authors:  A Schalhorn; H Sauer; W Wilmanns; G Stupp-Poutot
Journal:  Klin Wochenschr       Date:  1983-11-02

10.  Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.

Authors:  J Jolivet; B A Chabner
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.